BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays

Data ReadoutCobenfymilvexianNeutral

AI Analysis

Summary

Bristol Myers Squibb raised its 2026 outlook on strong quarterly results, but faces delays in Cobenfy Alzheimer's data and milvexian heart disease readout timelines.

Financial Highlights

Guidance

2026 outlook lifted

Outcome Details

Cobenfy Alzheimer's data delayed; milvexian heart disease readout pushed back

Importance:6/10

Sentiment:

0.20

delaydata readoutguidance raiseAlzheimer'scardiovascular

Related Companies

$BMY

Read the original article

Published by BioSpace on July 30, 2026 3:32 PM

Read Original